Get the Stockscreener App
97.43
0.62%
0.32
Lemaitre Vascular Inc stock is traded at $97.43, with a volume of 11,130.
It is up +0.62% in the last 24 hours and down -13.30% over the past month.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
See More
Previous Close:
$97.75
Open:
$97.94
24h Volume:
11,130
Relative Volume:
0.04
Market Cap:
$2.24B
Revenue:
$256.28M
Net Income/Loss:
$62.40M
P/E Ratio:
35.90
EPS:
2.7139
Net Cash Flow:
$79.12M
1W Performance:
-2.93%
1M Performance:
-13.30%
6M Performance:
+17.98%
1Y Performance:
+20.83%
1-Day Range:
$97.00
$99.77
1-Week Range:
$97.00
$102.66
52-Week Range:
$79.00
$118.01
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LMAT
Lemaitre Vascular Inc
|
97.86 | 2.23B | 256.28M | 62.40M | 79.12M | 2.7139 |
ISRG
Intuitive Surgical Inc
|
440.66 | 155.16B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
146.81 | 40.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.88 | 33.06B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.45 | 31.30B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
207.35 | 30.18B | 5.54B | 1.52B | 1.74B | 10.37 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
(LMAT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Thrivent Financial for Lutherans Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT - MarketBeat
Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & ConsumablesSpecialty Stocks - Yahoo Finance
LeMaitre Vascular to join two major healthcare investor conferences in June - Pluang
LeMaitre to Participate at Upcoming Investor Conferences in June - The Manila Times
LeMaitre schedules June talks at Jefferies and Goldman healthcare events - Stock Titan
GSA Capital Partners LLP Has $1.72 Million Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
Three Healthcare Stocks Facing Potential Headwinds in 2026 - IndexBox
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A Quick Look at Today's Ratings for LeMaitre Vascular(LMAT.US), With a Forecast Between $105 to $124 - Moomoo
Q3 2025 LeMaitre Vascular Inc Earnings Call Transcript - GuruFocus
Wakefield Asset Management LLLP Buys New Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call - Yahoo Finance
LeMaitre Vascular stock (US52567J1079): Q1 beat and raised 2026 guidance - AD HOC NEWS
[SCHEDULE 13G/A] LEMAITRE VASCULAR INC Amended Passive Investment Disclosure - Stock Titan
LeMaitre Vascular Senior Vice President of Operations Trent Kamke Sells 44% Of Holding - Moomoo
(LMAT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why LeMaitre Vascular (LMAT) Is Down 10.9% After Raising 2026 Guidance And Boosting Dividends - simplywall.st
Barrington Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Raises Target Price to $120 - 富途牛牛
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround - Yahoo Finance
LeMaitre Vascular Inc (NASDAQ:LMAT): A Quality Investing Candidate Passing All Caviar Cruise Screen Tests - ChartMill
Insider Transaction: George LeMaitre Sells $5.03M Worth Of LeMaitre Vascular Shares - Benzinga
LeMaitre Vascular stock (US52567J1079): Insiders sell amid recent price drop - AD HOC NEWS
Vanguard Group Inc. Boosts Stake in LeMaitre Vascular, Inc. $LMAT - MarketBeat
Lemaitre Vascular Insider Sold Shares Worth $5,032,413, According to a Recent SEC Filing - Moomoo
Insider Sell: Trent Kamke Sells Shares of LeMaitre Vascular Inc (LMAT) - GuruFocus
Lemaitre Vascular senior V.P. Kamke sells $313k in stock - Investing.com UK
Bridget Ross Sells 5,044 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Insider Trent Kamke Sells 2,928 Shares - MarketBeat
LeMaitre Vascular CEO George LeMaitre sells $5.03m in stock By Investing.com - Investing.com Nigeria
LeMaitre Vascular CEO George LeMaitre sells $5.03m in stock - Investing.com
LeMaitre Vascular(LMAT.US) Officer Sells US$5.03 Million in Common Stock - Moomoo
LeMaitre Vascular (LMAT) CEO sells 46,481 shares, retains over 1.4M - Stock Titan
Lemaitre Vascular director Lawrence J Jasinski sells $433,730 in stock By Investing.com - Investing.com Australia
Lemaitre Vascular director Lawrence J Jasinski sells $433,730 in stock - Investing.com UK
Lemaitre Vascular senior V.P. Kamke sells $313k in stock By Investing.com - Investing.com Canada
LeMaitre (LMAT) senior VP sells 2,928 shares in open-market trade - Stock Titan
Lemaitre Vascular Insider Sold Shares Worth $433,730, According to a Recent SEC Filing - Moomoo
LeMaitre Vascular (LMAT) director exercises options and sells 5,044 shares - Stock Titan
LeMaitre Vascular (LMAT) director exercises options, then sells 3,943 shares - Stock Titan
LeMaitre outlines 2026 targets including $280M revenue and $3 EPS as international Artegraft expands - MSN
LMAT (NASDAQ) restricted stock vesting noted; Trent G. Kamke sold shares under Rule 144 - Stock Titan
Number of shareholders of LeMaitre Vascular, Inc. – NASDAQ:LMAT - TradingView
LeMaitre Vascular Is Maintained at Equal-Weight by Wells Fargo - Moomoo
LeMaitre to Present at the Bank of America Healthcare Conference - The Manila Times
LeMaitre management takes Bank of America conference stage May 13 - Stock Titan
LeMaitre Vascular declares $0.25 dividend - MSN
[144] LEMAITRE VASCULAR INC SEC Filing - Stock Titan
Proposed LMAT common-stock sale by Morgan Stanley (LMAT) reported 05/07/2026 - Stock Titan
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):